PROJECT OVERVIEW
PROJECT DETAILS
- Fecha 3 de abril de 2025
- Sede Madrid
- Formato Presencial
Chairs:
Dr. Michael Jewett, Board Chair International Kidney Cancer Coalition (IKCC)
Dr. Ignacio Duran, Board member GUARD Consortium, Hospital Universitario Marques de Valdecilla, Santander
17:30-17:35 Opening
SCIENTIFIC CONTENT
17:35-18:00 KEYNOTE LECTURE
17:35-17:50 VHL as a target in mRCC in 2025: Where are we heading to?
Dr. Eric Jonasch, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
17:50-18:00 Q&A
18:00-18:55 SYSTEMIC TREATMENT IN RCC
18:00-18:15 RCC treatment in the perioperative setting: Where are we in 2025?
Dr. Teresa Alonso, Hospital Universitario Ramon y Cajal, Madrid
18:15-18:30 RCC treatment in the advanced disease: The role of sequencing after IO
Dr. Urbano Anido, Complexo Hospitalario Universitario de Santiago
18:30-18:45 RCC systemic treatment: The patient’s perspective in Spain
Dr. Juan Carlos Julián, Director General, Federación Nacional de Asociaciones ALCER, Madrid
18:45-18:55 Q&A
18:55-19:40 ROUND TABLE: Where are we and what do we need in mRCC in Spain in 2025?
Moderators:
Dr. Michael Jewett, Board Chair International Kidney Cancer Coalition (IKCC)
Dr. Ignacio Duran, Board member GUARD Consortium, Hospital Universitario Marques de Valdecilla, Santander
Discussants:
Dr. Pablo Maroto, Representative from GUARD Consortium
Dr. Juan Carlos Julián, Representative from Federación Nacional de Asociaciones ALCER
Dr. Abraham A. Ocanto, Representative from SEOR
Dr. Javier Puente, Representative from SEOM
19:40-19:45 Closing of the session
19:45 Cocktail
